Skip to main content
. Author manuscript; available in PMC: 2010 Dec 22.
Published in final edited form as: Biochemistry. 2009 Dec 22;48(50):11872–11882. doi: 10.1021/bi9014488

Figure 3. In vivo plaque reduction assay.

Figure 3

Wt influenza virus (A/Udorn/72) and influenza virus containing mutations in the M2 TM domain (V27A/L38F) were recovered from cloned DNA and assayed for plaque formation on MDCK cells in the presence or absence of drugs as described in Materials and Methods. A. Effects of amandadine, BL-1743 and compounds 8 and 9 (0.5 and 5 μM) on Udorn plaque formation. B. Effect of BL-1743 (50 and 100 μM) on influenza virus plaque formation. C. Effects of amantadine, BL-1743 and spiran amine 8 (50 μM) on influenza mutant virus V27A/L38F plaque formation. C, upper panel: ~1000 p.f.u./well of mutant virus were used. C, bottom panel: ~100 p.f.u./well of mutant virus were used. Plaque count: no drug – 99 plaques/well; amantadine 50μM – 82 plaques/well; BL-1743 50 μM – 86 plaques/well; spiran amine 8 50 μM – 37 plaques/well.